Literature DB >> 29042912

HPV vaccination in boys: Determining the clinical relevance of this strategy.

Harald Zur Hausen1, Ioannis N Mammas2, Demetrios A Spandidos2.   

Abstract

Entities:  

Keywords:  3rd Workshop on Paediatric Virology; Greece; Harald zur Hausen; human papillomavirus

Year:  2017        PMID: 29042912      PMCID: PMC5639420          DOI: 10.3892/etm.2017.5005

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


× No keyword cloud information.
Human papillomavirus (HPV) infection is an epitheliotropic viral infection (1) - described in the Hippocratic Corpus (2) -, which affects both adults and children (3). Almost 40 years after the first experiments, which investigated the link between HPV and cervical cancer (1), the implementation of vaccination against HPV into paediatric clinical practice represents one of the most significant steps towards the reduction of HPV-associated morbidity and mortality. The World Health Organisation (WHO) has recommended the establishment of HPV vaccination among girls (4), while the cost-effectiveness of HPV vaccination of girls exists even in low- and middle-income countries (5,6). To date, several studies have evaluated the health impact on the population of including males to HPV vaccination programmes (7), while in several countries, adolescent male vaccination has already been included into routine clinical practice (8). HPV has been proven to be an ‘equal opportunity’ pathogen affecting both sexes and adequate evidence supports the need to vaccinate adolescent boys and girls, before they become sexually active, in order to maximise the benefit of the highly effective HPV vaccines (9). Greece was one of the first countries of the European Union, which introduced the HPV vaccination programme for girls aged 11–12 years into its national scheme. Currently, the National Immunisation Committee of Greece has excluded teenage boys from the national scheme (10), while the achieved rates among adolescent girls have been described to be unacceptably low (11). As it will be highlighted in the context of the 3rd Workshop on Paediatric Virology, which will be held on Saturday the 7th of October in Athens, Greece (12), ‘if we really wish to eradicate these viral infections, we need to include boys into the vaccination programmes’ (13). However, it is yet unclear what should the optimal clinical practice be in Greece, a country ‘in the midst of a prolonged and deep economic recession that has already changed dramatically the lives of its citizens’ (14). The question of whether boys should also be vaccinated is as important as the necessity to eradicate cervical cancer. In this direction, the vaccination of boys can indeed offer significant clinical, economic and ethical advantages (15,16). Meanwhile, the increase in the currently low vaccination rates in females can represent a suitable target adding to the expected benefits that have been well described in the literature.
  14 in total

1.  Support for Greece.

Authors:  Harald zur Hausen
Journal:  Science       Date:  2012-05-25       Impact factor: 47.728

Review 2.  Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.

Authors:  Michaela Fesenfeld; Raymond Hutubessy; Mark Jit
Journal:  Vaccine       Date:  2013-07-03       Impact factor: 3.641

3.  Athens-based meeting to discuss the paediatric virology crossroad in October 2017.

Authors:  Ioannis N Mammas; Demetrios A Spandidos
Journal:  Acta Paediatr       Date:  2017-07-13       Impact factor: 2.299

4.  Vaccination against human papillomavirus in childhood: the next rubella analogue?

Authors:  I N Mammas; D A Spandidos
Journal:  J BUON       Date:  2012 Apr-Jun       Impact factor: 2.533

5.  Vaccination against Human Papillomavirus in relation to Financial Crisis: The "Evaluation and Education of Greek Female Adolescents on Human Papillomaviruses' Prevention Strategies" ELEFTHERIA Study.

Authors:  Ioannis N Mammas; Maria Theodoridou; Chryssie Koutsaftiki; George Bertsias; George Sourvinos; Demetrios A Spandidos
Journal:  J Pediatr Adolesc Gynecol       Date:  2015-12-24       Impact factor: 1.814

Review 6.  Human papilloma virus (HPV) infection in children and adolescents.

Authors:  Ioannis N Mammas; George Sourvinos; Demetrios A Spandidos
Journal:  Eur J Pediatr       Date:  2008-12-03       Impact factor: 3.183

7.  WHO position on HPV vaccines.

Authors: 
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

8.  Human Papillomavirus: The Equal Opportunity Pathogen.

Authors:  Patti E Gravitt
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 7.759

Review 9.  Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.

Authors:  Obinna I Ekwunife; James F O'Mahony; Andreas Gerber Grote; Christoph Mosch; Tatjana Paeck; Stefan K Lhachimi
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

10.  Incremental benefits of male HPV vaccination: accounting for inequality in population uptake.

Authors:  Megan A Smith; Karen Canfell
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more
  2 in total

1.  Paediatric virology and human papillomaviruses: An update.

Authors:  Ioannis N Mammas; Tina Dalianis; Sotiros G Doukas; Apostolos Zaravinos; Vassilis Achtsidis; Prakash Thiagarajan; Maria Theodoridou; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2019-04-22       Impact factor: 2.447

2.  Evaluating the proposal of paediatric virology: An interview with Professor Tina Dalianis, Professor of Tumour Virology at Karolinska Institutet.

Authors:  Ioannis N Mammas; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2018-07-31       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.